

COMIRNATY CLINICAL TRIAL

	Comirnaty	Placebo	Absolute/Relative Effectiveness	Commentary
Group size	22,000	22,000		
Adverse Events	6,600 30.00%	3,080 14.00%	-114% -16.00%	Net 16%
Severe Adverse Events	264 1.20%	154 0.70%	-71% -0.50%	Net 0.5%
Cases	77 0.35%	850 3.86%	91% 3.51%	Waning to 80% after 6 months
Cases (with prior infection)	2 0.01%	7 0.03%	71% 0.02%	Statistically insignificant
Severe Cases	1 0.00%	30 0.14%	97% 0.13%	Statistically insignificant
Deaths	15 0.07%	14 0.06%	-7% 0.00%	Not attributed to vaccine
Severe Adverse Events / Severe Cases	13x			
Severe Adverse Events / Cases (with prior infection)	46x			